428 related articles for article (PubMed ID: 22250080)
1. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
2. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.
Ståhl AL; Kristoffersson A; Olin AI; Olsson ML; Roodhooft AM; Proesmans W; Karpman D
Mol Immunol; 2009 Jul; 46(11-12):2236-43. PubMed ID: 19446882
[TBL] [Abstract][Full Text] [Related]
3. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
4. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
5. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
Frimat M; Tabarin F; Dimitrov JD; Poitou C; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
Blood; 2013 Jul; 122(2):282-92. PubMed ID: 23692858
[TBL] [Abstract][Full Text] [Related]
6. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
[TBL] [Abstract][Full Text] [Related]
8. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
Baker PJ; Adler S; Yang Y; Couser WG
J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
[TBL] [Abstract][Full Text] [Related]
9. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
10. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
11. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.
Pickering MC; Cook HT; Warren J; Bygrave AE; Moss J; Walport MJ; Botto M
Nat Genet; 2002 Aug; 31(4):424-8. PubMed ID: 12091909
[TBL] [Abstract][Full Text] [Related]
12. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.
Roumenina LT; Jablonski M; Hue C; Blouin J; Dimitrov JD; Dragon-Durey MA; Cayla M; Fridman WH; Macher MA; Ribes D; Moulonguet L; Rostaing L; Satchell SC; Mathieson PW; Sautes-Fridman C; Loirat C; Regnier CH; Halbwachs-Mecarelli L; Fremeaux-Bacchi V
Blood; 2009 Sep; 114(13):2837-45. PubMed ID: 19584399
[TBL] [Abstract][Full Text] [Related]
13. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
14. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
15. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
16. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
Lawrie CH; Sim RB; Nuttall PA
Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.
Møller-Kristensen M; Thiel S; Sjöholm A; Matsushita M; Jensenius JC
Int Immunol; 2007 Feb; 19(2):141-9. PubMed ID: 17182967
[TBL] [Abstract][Full Text] [Related]
20. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]